IRIS
MARTINI, Giulia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.186
NA - Nord America 1.089
AS - Asia 271
OC - Oceania 2
Totale 2.548
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.076
IE - Irlanda 472
IT - Italia 295
SG - Singapore 130
DE - Germania 128
GB - Regno Unito 74
CN - Cina 70
FR - Francia 53
UA - Ucraina 53
SE - Svezia 27
GR - Grecia 24
FI - Finlandia 23
KR - Corea 17
TR - Turchia 16
CA - Canada 13
CZ - Repubblica Ceca 12
PK - Pakistan 12
IN - India 9
BE - Belgio 7
VN - Vietnam 7
NL - Olanda 6
AT - Austria 4
HK - Hong Kong 3
AU - Australia 2
CH - Svizzera 2
ES - Italia 2
GI - Gibilterra 2
TW - Taiwan 2
HU - Ungheria 1
IR - Iran 1
JP - Giappone 1
KG - Kirghizistan 1
LK - Sri Lanka 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 2.548
Salva come PNG Salva come JPEG
Città #
Dublin 462
Chandler 220
Santa Clara 152
Jacksonville 94
Singapore 84
Naples 69
New York 64
Bremen 55
Princeton 54
Roxbury 54
Munich 36
Beijing 33
Ann Arbor 30
Cambridge 30
Caserta 24
Medford 24
Seoul 17
Los Angeles 14
Rome 12
Ashburn 11
Boardman 11
Brno 11
Des Moines 11
Elora 11
Wilmington 11
Napoli 9
Lappeenranta 8
Milan 8
Brussels 7
Helsinki 7
Dong Ket 6
Jinan 6
San Mateo 6
Woodbridge 6
Bahawalpur 5
Battipaglia 5
Mountain View 5
Nanjing 5
Anantapur 4
Houston 4
Istanbul 4
Pozzuoli 4
Vienna 4
Delhi 3
Ercolano 3
Montpellier 3
Norwalk 3
Acerra 2
Amsterdam 2
Andover 2
Auburn Hills 2
Avellino 2
Benevento 2
Cinquevie 2
Corbara 2
Fairfield 2
Florence 2
Groningen 2
Guangzhou 2
Hong Kong 2
Madrid 2
Matera 2
Menlo Park 2
San Nicola la Strada 2
Shanghai 2
Strasbourg 2
Tainan City 2
Taizhou 2
Toronto 2
Venice 2
Volta Mantovana 2
Zurich 2
Antea 1
Bangkok 1
Baoding 1
Bari 1
Berlin 1
Bezons 1
Bishkek 1
Bratislava 1
Cercola 1
Düsseldorf 1
Falconara Marittima 1
Formello 1
Frankfurt am Main 1
Galatone 1
Genova 1
Giugliano in Campania 1
Gunzenhausen 1
Hefei 1
Kai Tak 1
Konya 1
L'aquila 1
Lviv 1
Maharagama 1
Marcianise 1
Marigliano 1
Melbourne 1
Miami 1
Newark 1
Totale 1.787
Salva come PNG Salva come JPEG
Nome #
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 104
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 88
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 88
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 81
AXL is an oncotarget in human colorectal cancer 68
Beyond N staging in colorectal cancer: Current approaches and future perspectives 61
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 61
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 61
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 57
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 55
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case 50
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 50
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 48
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 47
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 47
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 47
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 46
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 45
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 44
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 43
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 42
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 42
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 41
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 41
Immunotherapy for head and neck cancer: Present and future 40
ROLE OF THE HEDGEHOG PATHWAY IN MEDIATING RESISTANCE TO ANTI-EGFR TYROSINE KINASE INHIBITORS IN NON SMALL CELL LUNG CANCER 39
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 39
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 39
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 38
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 38
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 38
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 37
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy 37
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 37
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation 36
Cancer cells adapt FAM134B/BiP mediated ER-phagy to survive hypoxic stress 36
Clinical management of metastatic colorectal cancer in the era of precision medicine 35
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 34
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 34
BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer 34
Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives 34
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression 32
Skin toxicity as predictor of survival in refractory patients with ras wild‐type metastatic colorectal cancer treated with cetuximab and avelumab (Cave) as rechallenge strategy 32
Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives 31
Pimasertib hydrochloride 30
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 29
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 28
Implication of the Hedgehog pathway in hepatocellular carcinoma. 28
How I treat anal squamous cell carcinoma 27
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 26
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 25
The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer 25
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 25
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 23
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941 22
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 21
Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer 21
Case report of unusual synchronous anal and rectal squamous cell carcinoma: clinical and therapeutic lesson 20
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 20
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 20
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer 19
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data 19
A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy 18
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. 18
RNF43- And NOTCH1-mutated chemotherapy and Anti-EGFR-refractory colorectal cancer: Should clonality guide target prioritization with investigational therapies? 18
Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update 17
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer 16
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial 15
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 13
Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments 13
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 13
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 11
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 11
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 7
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 7
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 6
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 5
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 5
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer 4
Targeting the EGFR signalling pathway in metastatic colorectal cancer 4
Totale 2.706
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.949
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.949
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020123 0 0 0 0 14 5 27 9 22 27 16 3
2020/2021184 13 11 18 8 18 1 21 21 12 22 28 11
2021/2022399 8 12 7 7 78 9 33 7 20 48 48 122
2022/2023939 99 17 25 71 125 78 4 41 426 8 26 19
2023/2024473 49 22 13 19 135 74 17 16 8 9 36 75
2024/2025387 42 39 30 63 213 0 0 0 0 0 0 0
Totale 2.706